Tag: Cellectis
Cellectis: will present data against cancer – 06/10/2022 at 11:10
(CercleFinance.com) – Cellectis will present preclinical data on “smart” CAR T cells edited by TALEN allowing better targeting of solid tumors, at the annual meeting of the Society for Immunotherapy…
Cellectis: activities funded until early 2024 – 08/05/2022 at 12:18
(CercleFinance.com) – The biotechnology company Cellectis ended the first half with cash of 135 million euros, which gives this genome editing specialist financial visibility until early 2024. Its consolidated sales…
Results of the Combined General Meeting of Shareholders of Cellectis SA of June 28, 2022
NEW YORK, June 28, 2022 (GLOBE NEWSWIRE) — The Combined General Meeting of Cellectis (Euronext Growth: ALCLS – Nasdaq: CLLS) was held on Tuesday, June 28, 2022 in Paris, at…
Results of the Combined General Meeting of Shareholders of Cellectis SA of June 28, 2022
NEW YORK, June 28, 2022 (GLOBE NEWSWIRE) — The Combined General Meeting of Cellectis (Euronext Growth: ALCLS – Nasdaq: CLLS) was held on Tuesday, June 28, 2022 in Paris, at…
Cellectis Announces Appointments of Axel-Sven Malkomes and Donald A Bergstrom, MD, Ph.D. to its Board of Directors
NEW YORK, June 28, 2022 (GLOBE NEWSWIRE) — Cellectis (Euronext Growth: ALCLS – Nasdaq: CLLS), a clinical-stage biotechnology company, which is using its pioneering TALEN® genome-editing technology to develop potential…
Cellectis: publication in sight
AS Published on 02/25/2022 at 07:28 Photo credit © Cellectis – Ramon Martinez…
Cellectis: the title folds after a placement of securities
(CercleFinance.com) – Cellectis lost almost 5% on the Paris Stock Exchange on Monday following a placement of shares and stock warrants by Calyxt, its American synthetic biology subsidiary based on…
Cellectis: The title folds after a placement of securities
Read also (CercleFinance.com) – Cellectis lost almost 5% on the Paris Stock Exchange on Monday following a placement of shares and stock warrants by Calyxt, its American synthetic biology subsidiary…
The way is clear for Allogene, partner of Cellectis, in the United States
The Food & Drug Administration, a US health authority, has lifted the notice of suspension of clinical trials for biotech, which had plunged Cellectis into the stock market in October.…
Cellectis: lifting of the suspension notice by the FDA – 11/01/2022 at 08:00
(CercleFinance.com) – Cellectis today declares that its licensed partner, Allogene Therapeutics has announced the lifting of the US Food and Drug Administration’s (FDA) suspension notice of its clinical trials. On…